Benzidine

CASRN 92-87-5

  • IRIS Summary (PDF) (16 pp, 129 K)
  • Status: Benzidine is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (16 pp, 129 K) last updated: 01/01/1989

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
3 x10-3 Nervous, Hepatic Brain cell vacuolization; liver cell alterations in females LOAEL : 2.7
mg/kg-day
1000 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (16 pp, 129 K) last updated: 07/01/1991
Information reviewed but value not estimated.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (16 pp, 129 K) last updated: 03/31/1987

WOE Characterization Framework for WOE Characterization
A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Observation of increased incidence of bladder cancer and bladder cancer-related deaths in exposed workers
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (16 pp, 129 K)

Oral Slope Factor: 2.3 x10 2 per mg/kg-day
Drinking Water Unit Risk: 6.7 x10 -3 per µg/L
Extrapolation Method: One-hit with time factor, extra risk
Tumor site(s): Urinary
Tumor type(s): Bladder tumors (Zavon, 1973)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (16 pp, 129 K)

Inhalation Unit Risk: 6.7 x10 -2 per µg/m3
Extrapolation Method: One-hit with time factor, extra risk
Tumor site(s): Urinary
Tumor type(s): Bladder tumors (Zavon, 1973)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.